What is MIMS Connect?

MIMS Connect articles are funded and provided by a selection of MIMS' partners from the commercial world of medicine.

The companies and their authors all have high levels of expertise in their particular field, and write on relevant topics that should be of interest to our GP audience.

Every article is first reviewed by the MIMS editorial team to ensure it meets our usual standards for publication.

The articles are clearly marked in a grey outline when listed on the website or in our email bulletins, and the text of each article includes a grey box detailing the source of the content.

We hope that MIMS readers will find this new initiative a useful addition to the content of the website. Please contact the editor with any comments or queries by emailing chloe.harman@haymarket.com.

To talk to our advertising team about participating in the MIMS Connect programme, please contact Michael Lok at michael.lok@haymarket.com or call 020 8267 4483.

Want news like this straight to your inbox?
Sign up for our bulletins

Have you registered with us yet?

Register now to enjoy more articles and free email bulletins

Already registered?
Sign in

More from MIMS

Drug shortages - live tracker

Drug shortages - live tracker

Added: fludroxycortide, levofloxacin, Noriday, Ongentys...

Vaping still safer than smoking, say health bosses after report of severe lung injury
Free online vestibular rehabilitation tool 'highly effective' for vertigo symptoms

Free online vestibular rehabilitation tool 'highly effective' for vertigo symptoms

GPs should consider online vestibular rehabilitation...

Thiazides better than ACE inhibitors as first-line antihypertensives, large-scale analysis suggests